• The New Money
  • Posts
  • Honeywell Aerospace Is Spinning Out, HUHUTECH Wins Japanese Semiconductor Facility Deal, And $500 Million For Rare Earth Processing

Honeywell Aerospace Is Spinning Out, HUHUTECH Wins Japanese Semiconductor Facility Deal, And $500 Million For Rare Earth Processing

The markets and trends that matter, made simple. Discover what’s next.

June 16, 2026

Honeywell Approves Spin Out Of Aerospace Company

Honeywell (NASDAQ: HON) officially approved the spin out of Honeywell Aerospace to become its own independent company. Honeywell Aerospace is one of the largest providers of mission critical system and technologies used in the vast majority of commercial, defense and space aircraft globally. The company has plans to make Honeywell Aerospace its own publicly traded company on the Nasdaq, and existing Honeywell shareholders would receive a share distribution.

HUHUTECH Wins New Deal From Japanese Semiconductor Company

HUHUTECH (NASDAQ: HUHU) won a new contract from a semiconductor manufacturing company in Japan for the supply and installation of vacuum exhaust pipeline insulation systems. HUHUTECH has publicly stated they spent more than a year developing their new nano-aerogel insulation technology and validating its performance in semiconductor manufacturing and fabrication environments.

Phoenix Tailings Lands $500 Million Loan From U.S. Government For Rare Earth Processing

Rare earth metal producer Phoenix Tailings was awarded a conditional funding commitment for a $500 million loan from The Pentagon’s Office of Strategic Capital in one of the single largest loans they have made to a private company. Phoenix Tailings publicly stated that the new loan will anchor a $1 billion financing commitment with private investors to accelerate the build out of their Freedom Facility for rare earth processing.

Conexeu Sciences: Architecting Bioregeneration

Conexeu Sciences (NASDAQ: CNXU) launched a preclinical development program for their 3D printed bioregenerative breast matrix which was recently successfully printed at the Wake Forest Institute for Regenerative Medicine.

The Sprint

Looking to connect? Reach out and get in touch.

New here? Join our community of 100,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.